To evaluate the effects of TNFα‐CSG on tumours, we focused on the RIP1‐Tag5 and 4T1 models because these tumours have different levels of immune infiltrates but share abundant ECM and thus CSG targets (Fig 1). The gene discussed is TNF; the disease is neoplasm.